Pulmonx Corp. (LUNG) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Pulmonx Corporation is a commercial-stage medical technology company providing minimally invasive treatments for severe emphysema, primarily through its Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and LungTraX Platform. This report covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 6 Months 2026 | YTD 6 Months 2025 |
|---|---|---|---|---|
| Revenue | $22.8 million | $23.9 million | $43.3 million | $46.4 million |
| Gross Profit | $17.7 million | $17.2 million | $33.8 million | $33.5 million |
| Gross Margin | 78.0% | 72.1% | 78.0% | 72.3% |
| Net Loss | $(10.1) million | $(15.2) million | $(23.7) million | $(29.6) million |
| Diluted EPS | $(0.24) | $(0.38) | $(0.56) | $(0.74) |
| Cash & Equivalents | $55.8 million (as of June 30, 2026) | |||
| Total Debt (Net) | $37.5 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4.6% in Q2 and 6.6% YTD compared to the prior year. The decline was driven by lower procedure volumes in the U.S. and a lack of sales in China due to a registration certificate renewal delay (renewed in June 2026).
- Margin Expansion: Gross margin improved significantly to 78.0% from 72.1% in Q2 2025, attributed to favorable geographic mix and reduced manufacturing costs relative to volume.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 18.5% in Q2 and 13.2% YTD, primarily due to reductions in payroll, advertising, and consulting costs.
- Debt Refinancing: In March 2026, the Company repaid its CIBC Loan ($37.0 million) and entered into a new $40.0 million term loan facility with Perceptive Credit Holdings (the "Perceptive Loan"). This increased interest expense due to a higher effective interest rate (13.9%) compared to the previous facility.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash ($55.8 million) is sufficient to fund operations for at least the next 12 months. The Company expects to continue incurring net losses.
- Debt Covenants: The Perceptive Loan requires maintaining minimum unrestricted cash of $4.0 million and meeting trailing 12-month revenue targets starting at $85.0 million (increasing to $107.5 million by 2030). The Company was in compliance as of June 30, 2026.
- China Market: Commercial activity in China is expected to resume by early 2027 following the June 2026 registration renewal.
- Risks: Key risks include dependence on the single Zephyr Valve product, reimbursement challenges (Medicare covers on a case-by-case basis), potential supply chain disruptions from single-source suppliers, and the high cost of capital associated with the new debt facility.
Investor Verification Checklist
- China Recovery: Verify the timeline for resuming shipments to the Chinese distributor and the impact on Q3/Q4 revenue.
- Debt Service: Monitor cash burn against the $4.0 million minimum cash covenant and the ability to meet the $85.0 million trailing revenue threshold.
- Reimbursement Trends: Assess the rate of prior authorization approvals from commercial payors and any changes in Medicare coverage policies.
- Interest Expense: Track the impact of the 13.9% effective interest rate on the Perceptive Loan on future net losses.
- Product Pipeline: Review progress on the AeriSeal System (CONVERT II trial) as a potential growth driver beyond the Zephyr Valve.